Pierre Fabre to Commercialize and Distribute the First Approved Allogeneic T-cell Immunotherapy in Europe Following Transfer of the European Commission Marketing Authorization of EBVALLO™ (tabelecleucel)
From today, Pierre Fabre will lead all commercialization, distribution, medical and regulatory activities in Europe, Middle East, Africa and other selected markets.
- From today, Pierre Fabre will lead all commercialization, distribution, medical and regulatory activities in Europe, Middle East, Africa and other selected markets.
- Pierre Fabre is planning to launch EBVALLO™ in the first European countries during quarter one of 2023.
- The EC marketing authorization is based on results from the pivotal Phase 3 ALLELE study and additional supportive studies.
- Atara retains full rights to EBVALLO™ in other major markets, including North America, Asia Pacific, and Latin America.